Center for Molecular Prediction of Inflammatory Bowel Disease

Medicine and Dentistry

1. Adult 17%
2. Age 13%
3. Allergic Rhinitis 6%
4. Anal Fistula 6%
5. Analysis 10%
6. Antibiotics 7%
7. Association 11%
8. Attention Deficit Disorder 6%
9. Autoimmune Pancreatitis 6%
10. Biodiversity 6%
11. Biological Product 15%
12. Birth Outcomes 6%
13. Bowel Resection 6%
14. Cancer Risk 6%
15. Cancer Staging 6%
16. Cervical Cancer 6%
17. Child 8%
18. Cohort Analysis 100%
19. Cohort Effect 8%
20. Colectomy 12%
21. Colitis 7%
22. Colonoscopy 5%
23. Colorectal Cancer 15%
24. Consensus 13%
25. Crohn's Disease 51%
26. Cyclosporine 6%
27. Death 6%
28. Desensitization 6%
29. Development 10%
30. Diagnosis 50%
31. Disease Activity 6%
32. Disease Course 20%
33. Diseases 25%
34. Drug 6%
35. Drug Repositioning 6%
36. Drug Therapy 9%
37. Dysplasia 8%
38. Endocrine Disease 6%
39. Eosinophilic Esophagitis 6%
40. Experience 5%
41. Family 6%
42. Family History 7%
43. Fistula 5%
44. Follow up 6%
45. Gastroenterology 6%
46. Genital Wart 6%
47. Glucagon Like Peptide 1 6%
48. Glucocorticoid 5%
49. Glycon 7%
50. Hazard Ratio 40%
51. Hospital 18%
52. Immunosuppressive Drug 8%
53. Incidence 10%
54. Infant 7%
55. Infection 16%
56. Inflammatory Disorder 8%
57. Infliximab 6%
58. Inpatient 69%
59. Lactation 6%
60. Lesion 6%
61. Life 11%
62. Lifestyle 6%
63. Malignant Neoplasm 23%
64. Maturity Onset Diabetes of the Young 8%
65. Meta-Analysis 22%
66. Microbiome 7%
67. Microscopic Colitis 6%
68. Obstructive Lung Disease 6%
69. Odds Ratio 19%
70. Older Adult 13%
71. Patient 87%
72. Patient Registry 6%
73. Patient with Crohn's Disease 19%
74. Patient with Inflammatory Bowel Disease 60%
75. Patient with Ulcerative Colitis 7%
76. Pediatrics 12%
77. Pediatrics Patient 6%
78. Person 11%
79. Personalized Medicine 13%
80. Postpartum Depression 6%
81. Pouchitis 13%
82. Prognosis 8%
83. Prognostication 8%
84. Proportional Hazards Model 7%
85. Rectum Cancer 6%
86. Severe Acute Respiratory Syndrome Coronavirus 2 6%
87. Spontaneous Remission 5%
88. Systematic Review 8%
89. Therapeutic Procedure 48%
90. Tuberculosis 6%
91. Tumor Necrosis Factor 26%
92. Ulcerative Colitis 40%
93. Vedolizumab 14%
94. Vermiform Appendix 6%
95. Woman 21%